Clinical trial
Long-Acting Lanreotide as a Volume Reducing Treatment of Polycystic Livers
NCT00565097 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Long-Acting Lanreotide as a Volume Reducing Treatment of Polycystic Livers
- Lead sponsor
- Radboud University Medical Center
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- October 31, 2007
- Completion date
- Not reported
- Enrollment
- 38 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
hepatomegaly, liver diseases, polycystic kidney, autosomal dominant, polycystic liver disease